SGLT2 inhibitors and GLP1RA may potentially aid in the improvement of long COVID-19 through various mechanisms, including better control of high blood sugar, blood pressure, weight, oxidative stress, insulin resistance, and chronic low-level inflammation [31]. This evidence concerns the gene SLC5A2 and COVID-19.